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IMPACT OF DEPENDENTS’ DEPRESSION ON
EMPLOYEE HEALTH BENEFITS COST:
QUANTIFYING THE BURDEN OF CARE
Kleinman N, Muchmore L, Gardner H
Options & Choices, Inc, Cheyenne, WY, USA
OBJECTIVES: This analysis quantiﬁes the difference in
employee health beneﬁts cost between employees with at
least one dependent with depression and employees with
no depressed dependents. Healthcare, sick leave, short-
and long-term disability and workers’ compensation
claims data are used along with employee population data
to quantify the increased employee costs associated 
with having a dependent with depression. METHODS:
Using data from 1998, this study examines 42,000 
geographically-disperse employees. An employee was
deﬁned to have a dependent with depression if any of the
employee’s dependents had a healthcare claim during
1998 with a primary ICD9 code signifying depression.
Employees without any dependents were excluded from
the analysis. Censored (tobit) regression models were
used to control for the impacts of age, gender, exempt
status, number of covered dependents, and regional dis-
tribution and to isolate the impact of having a depressed
dependent on the health beneﬁts costs incurred by the
employee. RESULTS: Employees with depressed depen-
dents incurred 99% higher healthcare costs (excluding
dependent healthcare costs) (p < 0.0001) and 27% higher
sick leave costs (p < 0.01) than did employees without
depressed dependents. CONCLUSIONS: An employee
whose dependent has depression has signiﬁcantly higher
health beneﬁts costs than an employee whose dependents
do not have depression. Thus, employers must recognize
the impact of dependent health issues on employee health
and productivity costs. Employers may use this informa-
tion to design or reﬁne EAP and other mental health pro-
grams to account for issues associated with the burden of
care.
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TREATMENT OF DEPRESSION: ESCITALOPRAM
HAS SIMILAR EFFICACY BUT LOWER COSTS
COMPARED TO VENLAFAXINE XR
Montgomery SA1, Fernandez JL2, François C3
1Imperial College, London, United Kingdom; 2London School
of Economics, London, United Kingdom; 3Lundbeck SA, Paris,
France
OBJECTIVES: Major depressive disorder presents a 
considerable burden of illness to patients, healthcare
providers and payers. The introduction of SSRIs and
SNRIs was noteworthy, but there are still patients who
do not receive the full beneﬁt of these drugs. Our objec-
tive was to assess the relative cost-effectiveness of esci-
talopram compared to venlafaxine XR in a randomised,
double-blind, active-reference clinical study. METHODS:
Outpatients fulﬁlling DSM IV criteria for a major depres-
sive episode were randomised to receive escitalopram (10
to 20mg/day; n = 148) or venlafaxine (75 to 150mg/day;
n = 145) in a double-blind study in a primary-care setting
in Europe. In addition to clinical evaluations, assessments
of generic quality of life (EuroQoL) were made at study
entry and after eight weeks of treatment. Use of medical
services and absence from work were recorded for the cal-
culation of direct and indirect costs from the perspective
of society and healthcare budgets. Multivariate model-
ling of costs controlling for patient characteristics was
applied. For cost-effectiveness analysis, two efﬁcacy mea-
sures were used (MADRS and EuroQoL). RESULTS:
Statistically signiﬁcant quality of life improvements from
baseline were observed in both treatment groups, with 
no between-group differences. At the end of the study, 
escitalopram costs, compared to venlafaxine, were 10%
lower (€747.5 versus €830.6) from a societal perspective,
and 40% lower (€84.3 versus €141.5) from a healthcare
perspective. Results of the multivariate model show that
escitalopram tends to reduce direct costs (p = 0.03). 
Bootstrapped distributions of the Incremental Cost-
Effectiveness Ratios support the cost-effectiveness advan-
tage of escitalopram. CONCLUSIONS: With similar
effectiveness, escitalopram tends to lead to lower costs.
These results are consistent with results of previous eco-
nomic evaluation of escitalopram versus venlafaxine.
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THE COST-UTILITY OF BUPROPION SR VERSUS
SERTRALINE IN THE TREATMENT OF LATE-LIFE
DEPRESSION
Suter KL, Biddle A
University of North Carolina at Chapel Hill, Chapel Hill, NC,
USA
OBJECTIVES: Major depression affects 10 to 35% of
community dwelling elderly and left untreated, is associ-
ated with increased healthcare expenditures and risk 
of non-suicide mortality. Pharmacotherapy treatment of
depression in the elderly warrants special consideration
due to pharmacokinetic changes and polypharmacy. The
objective of this study was to estimate the incremental
cost-utility of sertraline (Zoloft, Pﬁzer) compared to
bupropion SR (Wellbutrin SR, GlaxoSmithKline) in a
population of community dwelling elderly with a diag-
nosis of major depression. METHODS: Decision tree
modeling was used to calculate the incremental cost-
utility for a hypothetical cohort of 1000 elderly patients
with diagnosed major depression over a time period of
one-year from a societal perspective. Parameter estimates
were obtained from a comprehensive review of published
literature. Extensive sensitivity analysis was used to test
each parameter. RESULTS: In the base-case analysis,
bupropion SR treatment cost US$ 3.2 million and resulted
in 777 quality-adjusted life years (QALYs), dominating
sertraline treatment (US$3.5 million; 704 QALYs). One-
way sensitive analysis yielded two sensitive utilities.
Further examination of these utilities in a multi-way
